TWST logo

TWIST BIOSCIENCE CORP

TWSTNASDAQ
πŸ† #841 by market capEarnings Nov 12 Β· PreUS Equity
$173.47β–² $13.60 (+8.51%)
After hours Β· at close
πŸ””
Track TWST
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 8.5%
7dβ–² 16.3%
14dβ–² 17.1%
30dβ–Ό 3.4%
ytdβ–² 447.1%
1yβ–² 416.9%
🏦Market Cap
$11.42B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
20.3%
Healthy
πŸ“ŠGross Margin
52.0%
Healthy
πŸ’΅FCF Margin
-21.6%
Thin
βš–οΈP/S Ratio
22.1x
Expensive
Otter Score
52
Fair

Trading Snapshot

Day Range
$159.70 – $178.27
52-Week Range
$23.30 – $219.71
Volume (shares)
196,915
Avg Volume (shares)
β€”
Shares Outstanding
65.8M
Next Earnings
2026-11-12

Fundamentals Snapshot

Annual Revenue
$377M
Last Q Revenue
$118M
P/E Ratio
-65.4
P/S Ratio
22.1x
EPS (TTM)
$-2.19
Dividend Yield
0.00%
Dilution (1yr)
+3.2%
TWST logo

TWIST BIOSCIENCE CORP

TWST
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$377Mβ–² +20.3% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
50.7%β–² +19.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$136Mβ–Ό βˆ’38.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$76Mβ–² +9.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
61.1Mβ–² +3.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$35Mβ–Ό βˆ’$174M YoY
StockOtter Β· stockotter.space

About TWIST BIOSCIENCE CORP

Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
52/100

Analyst Ratings

β“˜
Consensus
Buy
18 analysts
Strong Buy7
Buy7
Hold3
Sell1
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.